Patents for A61P 35 - Antineoplastic agents (221,099)
05/2008
05/08/2008WO2008011109A3 Substituted pyridone compounds and methods of use
05/08/2008WO2008009963A3 Pyrimidine derivatives as modulators of parathyroid hormone receptors
05/08/2008WO2008001219A3 Cancer therapy using bcl-xl-specific sina
05/08/2008WO2007149381A3 Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
05/08/2008WO2007147480A3 Polymorphic forms and process
05/08/2008WO2007146138A3 Thiadiazole compounds and methods of use thereof
05/08/2008WO2007139930A3 Drug combinations with substituted diaryl ureas for the treatment of cancer
05/08/2008WO2007138116A3 Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
05/08/2008WO2007129226A3 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
05/08/2008WO2007120752A3 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
05/08/2008WO2007098033A3 Feedback prodrug
05/08/2008WO1999048916A8 Hypoxia-inducible human genes, proteins, and uses thereof
05/08/2008US20080108819 Novel indole derivatives and their use as medicament
05/08/2008US20080108808 Dipeptidyl peptidase inhibitors
05/08/2008US20080108807 Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile
05/08/2008US20080108708 Method for Producing Albumin Conjugates Containing Gyrase Inhibitors
05/08/2008US20080108707 treating with honokiol, honokiol-type compound or magnolol, magnolol-type compound; skin disorders, cancer
05/08/2008US20080108697 Using a glass bottle containing oxaliplatin in aqueous solution at a concentration between 2 mg/ml and 7 mg/ml; metastatic colorectal cancers; surface/volume ratio of the flask, expressed in mm2/mm3, is less than 0.26
05/08/2008US20080108694 Inhibit the growth of or kill Rb negative cancer cells; inhibit the activity of Heat shock protein 90; antibiotics, antimalarial agents, anticancer agents, antitumor agents; cytotoxicity; to treat glioblastoma, lung cancer and retinoblastoma
05/08/2008US20080108693 N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl taxol; antitumor activity; chemical stability
05/08/2008US20080108692 Alkylene selenocyanate or an alkylene isoselenocyanate moiety; anticancer agents; food supplements; 1,4-phenylenebis(alkylene)selenocyanate
05/08/2008US20080108690 chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one
05/08/2008US20080108677 Thioxothiazolidinone Compounds For Use As Pharmaceuticals
05/08/2008US20080108675 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
05/08/2008US20080108672 Inorganic or organic acid salts or basic salts of N-methylcarbamoylphenoxy and N-methylcarbamoylpyridyloxy-substituted diphenylureas; N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea tosylate; carcinoma of the lung, pancreas, thyroid, bladder or colon.
05/08/2008US20080108659 Poly(adp-ribose)polymerase inhibitors
05/08/2008US20080108657 Used to treat cancer including leukemia, mesothelioma, lung cancer, colorectal cancer, breast cancer, ovarian cancer, prostate cancer, melanoma, cancer of the uterine body and cancer of the central nervous system; nontoxic
05/08/2008US20080108655 Administering orphenadrine and chloroquine
05/08/2008US20080108654 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate
05/08/2008US20080108648 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
05/08/2008US20080108644 alkaloids; anticarcinogenic, antiproliferative agent; inhibitor of cellular mitosis and cell proliferation; binding to tubulin leads to cell cycle arrest in M phase and subsequently to apoptosis; antiallergen, antiinflammatory, antidiabetic, autoimmune diseases; asthma, arthritis, Alzheimer' disease
05/08/2008US20080108642 Matrine, oxymatrine, and sinomenine (hydrochloride); rheumatoid arthritis and cancer
05/08/2008US20080108641 Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
05/08/2008US20080108636 compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told
05/08/2008US20080108628 Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug
05/08/2008US20080108627 9-[(3-hydroxy-5-methoxyphenyl)amino]-1,2-dihydrothieno[3,2-f]quinoline-8-carbonitrile 3,3-dioxide; protein tyrosine kinases inhibitor, especially erythropoetin-producing hepatoma amplified sequence (Eph) receptors antagonist; antitumor, angiogenesis inhibitor, neurodegenerative diseases
05/08/2008US20080108625 Substituted Triazole Derivatives as Oxytocin Antagonists
05/08/2008US20080108623 N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent
05/08/2008US20080108616 as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; lung; 4-(3-Trifluoromethyl-phenylamino)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-(4-morpholin-4-yl-phenylcarbamoyl)-phenyl]-amide
05/08/2008US20080108615 such as 4-(1-Hydroxyimino-indan-5-yl)-5-pyridin-4-yl-1H-imidazole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; anticarcinogenic agents, neurodegenerative diseases, brain disorders, stroke, antischemic agent
05/08/2008US20080108613 Pyrazolopyrimidine Compounds as Antitumor Agents
05/08/2008US20080108612 Use of Purine Derivatives as HSP90 Protein Inhibitors
05/08/2008US20080108611 Substituted thienopyrimidine kinase inhibitors
05/08/2008US20080108608 Pyrimidines With Tie2 (Tek) Activity
05/08/2008US20080108606 Side effect reduction; antiproliferative agents; schizophrenia
05/08/2008US20080108601 anticancer agents; catalytic hydrogenation
05/08/2008US20080108582 Methods And Compositions For Combinatorial Approaches To Cancer Gene Therapy
05/08/2008US20080108581 consist of DNA sequence-specific ligand capable of recognizing sequence common to genes of pathological interest ( as IGF-1, IGF-1R, VEGF, BCL2), linker arm, and topoisomerase I posion (as camptothecins, rebeccamycins, minor groove ligands, benzimidazoles); dismetabolic, autoimmune diseases, HIV and HCV
05/08/2008US20080108576 Novel cytostatic conjugates with integrin ligands
05/08/2008US20080108564 Peptide covalently bound to Polyethylene glycol; agonists of the erythropoietin receptor (EPO-R), having amino acid sequence; defective red blood cell production
05/08/2008US20080108559 Compositions and methods for treating diseases through inhibition of dna methylation and histone deacetylase
05/08/2008US20080108552 Beta 1-integrin inhibitory peptide modified by biotin, cystein, or carboxyfluorescein (FAM)
05/08/2008US20080108549 Actin proteins as biomarkers for indication and targeting of resistance and sensitivity to an Abl kinase inhibitor in patients with chronic myelogenous leukemia
05/08/2008US20080108545 Peptide nucleic acid linked via a disulfide bond to a triphenylphosphonium group; deliver PNA oligomers across the plasma membrane into cells; HIV infection, hepatitis C infection; melanoma, pancreatic adnocarcinoma, actue myeloid leukemia, myeloma, small cell lung cancer, prostate cancer
05/08/2008US20080108135 Using immunoglobulin fusion to deliver effector cells; tissue targeted therapy; antitumor agents
05/08/2008US20080107760 Beverage and medicament containing bamboo extract as a main ingredient
05/08/2008US20080107721 Combination Chemotherapy Comprising A Liposomal Platinum Complex
05/08/2008US20080107720 Topical delivery of codrugs
05/08/2008US20080107693 Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences
05/08/2008US20080107686 Such as granulocyte-macrophage colony stimulating factor; cytokines; kits; capsules
05/08/2008US20080107668 Oligopeptides comprising epitopic sequences for use in induction of killer lymphocyte response in treatment of cell proliferative disorders
05/08/2008US20080107659 Pharmaceutical Compositions for the Prevention and Treatment of Atherosclerosis and Restenosis After PTCA
05/08/2008US20080107630 Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus
05/08/2008US20080107605 From a clone comprising complete nucleotide sequence for the expression of the TSH
05/08/2008US20080107604 Method for the Prediction of the Risk Potential for Cancerous Diseases and Inflammatory Intestinal Diseases and Corresponding Tests
05/08/2008US20080107599 Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging
05/08/2008DE20221790U1 Koagulationsaktives Antithrombin III und dessen Verwendung zur Prophylaxe und Therapie von Angiogenese-abhängigen Erkrankungen Koagulationsaktives antithrombin III and its use for the prophylaxis and therapy of angiogenesis-dependent diseases
05/08/2008DE102006051796A1 Triaza-benzo[e]azulenderivate Triaza-benzo [e] azulene derivatives
05/08/2008CA2668562A1 Triazabenzo(e)azulene derivatives for the treatment of tumours
05/08/2008CA2668537A1 Composition for the treatment of gastrointenstinal diseases
05/08/2008CA2668363A1 A method of administering an antitumor compound
05/08/2008CA2668255A1 Anilinopiperazine derivatives and methods of use thereof
05/08/2008CA2668210A1 Anilinopiperazine derivatives and methods of use thereof
05/08/2008CA2668209A1 Anilinopiperazine derivatives and methods of use thereof
05/08/2008CA2668027A1 Fgfr4 promotes cancer cell resistance in response to chemotherapeutic drugs
05/08/2008CA2668017A1 Improved conjugates
05/08/2008CA2668010A1 Organo-arsenoxide compounds and use thereof
05/08/2008CA2667970A1 Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type ii receptor (amhr-ii)
05/08/2008CA2667960A1 Imidazopyridazines as pi3k lipid kinase inhibitors
05/08/2008CA2667927A1 3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
05/08/2008CA2667839A1 Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
05/08/2008CA2666316A1 Pai-1 binding modulators for the treatment of ocular disorders
05/08/2008CA2634783A1 Anti-hyperproliferative therapies targeting hdgf
05/07/2008EP1918716A2 Screening for agents modulating TGF-Beta cell signalling
05/07/2008EP1918380A2 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
05/07/2008EP1918377A1 Mammalian cytokine receptor subunit proteins, related reagents and methods
05/07/2008EP1918376A1 FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
05/07/2008EP1918366A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
05/07/2008EP1918305A1 New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
05/07/2008EP1918304A1 Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
05/07/2008EP1918303A2 method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
05/07/2008EP1918301A1 RGD-enriched gelatine-like proteins for inhibition of cancer metastasis
05/07/2008EP1918292A1 Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
05/07/2008EP1918287A2 LPA receptor agonists and antagonists and methods of use
05/07/2008EP1918278A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
05/07/2008EP1918277A2 Azulene compounds
05/07/2008EP1917977A1 Therapeutic drug for heart disease and virus disease
05/07/2008EP1917970A2 Hla binding peptides and their uses
05/07/2008EP1917968A1 Methods and composition for complementing treatments to eradicate neoplastic cells
05/07/2008EP1917965A1 Inhibitors of the mutant form of KIT